Supernus, Inc. (INDV) company profile
Close on Oct 30, 2026Market cap $4.17BP/E 9.9Yield –
About Supernus
Pharmaceutical Preparations, SIC 2834
Indivior Pharmaceuticals, Inc. develops and commercializes prescription medicines focused on treating opioid use disorder and related conditions. Its principal commercial offerings include SUBLOCADE, an extended-release monthly injectable suspension, and SUBOXONE Film, a sublingual formulation combining buprenorphine and naloxone. The company also provides SUBUTEX sublingual tablets in select international markets. Through these pharmacotherapies, Indivior serves individuals diagnosed with opioid dependence as well as healthcare providers and clinical systems managing substance use recovery programs.
Headquartered in Richmond, Virginia, in the United States, Indivior primarily concentrates its sales operations within the domestic U.S. market. Beyond the United States, the company distributes treatments internationally across Canada, Australia, France, and Germany. Indivior additionally maintains an active pharmaceutical ingredient manufacturing facility in Hull, United Kingdom, along with support personnel based in Slough and Hull to support its international and domestic operations.
Summary of the business section of Supernus's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Supernus, Inc.
- Founded
- 2014
- Headquarters
- North Chesterfield, VA
- Address
- 10710 Midlothian Turnpike, Suite 125 23235
- Phone
- (804) 379-1090
- Website
- indivior.com
- Employees
- 838, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Richmond, Virginia
Stock & identifiers
- Ticker
- INDV
- Other tickers
- SUPN
- Exchange
- Nasdaq
- IPO date
- Dec 29, 2014
- Shares outstanding
- 118M, Oct 9, 2026
- Public float
- $1.83B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1625297
- CUSIP
- 45579U109
- ISIN
- US45579U1097
- FIGI
- BBG01ZTXFLQ6
- Share class FIGI
- BBG01ZTXFLX8
- LEI
- 254900MKFFZZSS7N1I14
- EIN
- 41-2520873
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jack A. Khattar | Chief Executive Officer, Director | 3,413,555 |
| Joseph Ciaffoni | Chief Executive Officer, Director | 790,330 |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | 30,099 |
| Timothy C. Dec | SVP, Chief Financial Officer | 14,059 |
| Jonathan Rubin | SVP, Chief Medical Officer | 21,529 |
| Padmanabh P. Bhatt | SVP of IP, CSO | 28,702 |
| William Todd Horich | SVP, Chief Commercial Officer | – |
| Woodrow D. Anderson | Chief Accounting Officer | 27,638 |
| Christian Heidbreder | Chief Scientific Officer | 209,337 |
| Ryan Preblick | Chief Financial Officer | 284,751 |
| Jeffrey W. Burris | Chief Legal Officer | 71,518 |
| Patrick A. Barry | Chief Commercial Officer | 31,380 |
| Bethany Sensenig | Director | – |
| Georges Gemayel | Director | 42,009 |
| Carrolee Barlow | Director | 41,652 |
| Barbara Ryan | Director | 12,242 |
| David E. Wheadon | Director | 30,780 |
| Stuart A. Kingsley | Director | 12,100 |
| Mark Stejbach | Director | 27,087 |
| Daniel A. Ninivaggi | Director | 27,163 |
| Keith Humphreys | Director | 16,042 |
| Juliet Thompson | Director | 18,748 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Joe Ciaffoni | $18.50M | $63.34M | $4.04M | $165 | $135 |
| FY2025 Mark Crossley | $3.19M | $19.30M | $4.04M | $165 | $135 |
| FY2024 | $3.85M | $1.19M | $2.49M | $57 | $102 |
| FY2023 | $4.39M | -$5.54M | $2.77M | $70 | $104 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Joe Ciaffoni Chief Executive Officer (3) | $680.11K | – | $15.32M | $2.10M | $401.70K | $18.50M | – |
| Mark Crossley Former Chief Executive Officer (4) | $902.26K | – | $162.52K | $2.05M | $66.29K | $3.19M | -17% |
| Ryan Preblick Chief Financial Officer (5) | $558.82K | – | $2.30M | $670.58K | $59.92K | $3.59M | +57% |
| Christian Heidbreder Chief Scientific Officer (6) | $652.63K | – | $2.69M | $783.15K | $57.09K | $4.18M | +67% |
| Pat Barry Chief Commercial Officer (7) | $408.33K | $300.00K | $3.25M | $840.00K | $110.04K | $4.91M | – |
| Jeff Burris Chief Legal Officer (8) | $569.00K | – | $2.34M | $569.00K | $45.35K | $3.52M | +79% |
| Richard Simkin Former Chief Commercial Officer (9) | $325.01K | – | $2.97M | $448.78K | $274.87K | $4.02M | +26% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, the Company employed 838 people worldwide, of which 827 were full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 2, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 2, 2026 | Name change | Name changed from Indivior Pharmaceuticals, Inc. to Supernus, Inc. |
| Aug 28, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jan 26, 2026 | Deregistration | Termination of SEC registration (Form 15) |
| Jan 8, 2026 | Name change | Name changed from INDIVIOR PLC to Supernus, Inc. |
See a number that looks wrong?